USV to take Fujix cures worldwide

MUMBAI: City-based pharma company USV Ltd has inked a deal with Fujix Corp of Japan for acquiring the worldwide marketing rights for three products.

Under the deal signed two days ago, the Rs 600-crore USV will market Fujix’s calcium supplement Triple-A Cal, magnesium supplement Double-A-Mag and an oral anti-wrinkle therapy all over the world except in the US and Japan. In fact, Triple-A Cal, which was launched in India two years back, is claimed to be the largest selling calcium supplement in the country with sales of Rs 16 crore.

Under the deal, USV, a major player in the diabetes and cardiology segments, will be launching a few more products from Fujix in future. Sources said the company is also in talks with a few other pharmaceutical companies for marketing tie-ups.

Since India entered the product patent regime in 2005, most mid-sized pharma companies have followed the strategy of in-licensing or acquiring marketing rights for drugs from foreign companies.

Earlier this year, USV signed marketing deals with Kissei of Japan for a diabetes drug and with German firm Sebapharma for Sebamed (cosmeceuticals).